NewsRelease
PatentCites Viraffinity™ for Dengue Virus (DV) Purification
MONMOUTHJUNCTION, NJ,July31, 2018 --BiotechSupport Group reports on a recent patent describing the simplicityand efficiency of their virus enrichment technology for viralproteomic analyses from plasma.
Thecitation is:
Bedin,Frédéric, and Romain Fragnoud. "Methodand kit for determining the probability that a patient will develop asevere case of dengue." U.S.Patent Application No. 15/912,730.
Inbrief, the patent application describes claims determining whether apatient will develop severe dengue based on a blood sample. In theexample, virions were purified from plasma pools of patients withdengue fever or severe dengue. For purification, virions were firstenriched by ultracentrifugation and then subsequently purified byViraffinity™. The patent application states “…resuspensionis then purified using an insoluble polyelectrolyte, Viraffinity(BioSupportGroup, USA). For this purpose, 200 microliters of an MNbuffer (60 mM MES pH 6.5, 150 mM NaCl) are added to the viralsuspension along with 100 microliters of Viraffinity. The mixture isincubated for 5 min at room temperature then centrifuged for 10 minat 1000×g, following supplier instructions. The supernatant isremoved and the polymer pellet is rinsed 3 times with 200 microlitersof MN buffer. …The presence of the virus in the final samples wasverified by immunoblotting with a monoclonal antibody directedagainst the envelope protein of the dengue virus (E protein).”.
“Thispatent application follows previously reported research wherebyViraffinity™complements the gold-standard of enrichment using gradientultracentrifugation. I am very pleased that the exquisite selectivityprofile of Viraffinity™was in-part the reason the patent’s authors were able to obtain anexcellent viral protein signal by Western blot” states Swapan Roy,Ph.D., President and Founder of Biotech Support Group.
Formore information visit: Viraffinity™,at
http://www.biotechsupportgroup.com/Viraffinity-Virus-and-Viral-Component-Isolation-p/v1062.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866,[email protected]